Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INM NASDAQ:KZIA NASDAQ:TPST NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMInMed Pharmaceuticals$1.58+4.6%$1.01$0.58▼$5.50$5.24M0.98986,489 shs30,742 shsKZIANovogen$12.54+9.0%$11.49$4.86▼$17.40$20.73M2.17220,898 shs352,054 shsTPSTTempest Therapeutics$1.25-1.6%$1.76$1.23▼$12.23$18.51M-1.85165,549 shs41,344 shsXCURExicure$2.82+2.2%$3.40$2.62▼$9.75$17.98M3.5325,027 shs13,871 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMInMed Pharmaceuticals-1.31%-4.13%+143.16%+88.75%-45.49%KZIANovogen+0.70%+5.02%-18.44%+43.57%+118.63%TPSTTempest Therapeutics0.00%0.00%-34.54%-44.54%-85.70%XCURExicure-3.16%-10.39%-18.34%-30.39%-72.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMInMed Pharmaceuticals$1.58+4.6%$1.01$0.58▼$5.50$5.24M0.98986,489 shs30,742 shsKZIANovogen$12.54+9.0%$11.49$4.86▼$17.40$20.73M2.17220,898 shs352,054 shsTPSTTempest Therapeutics$1.25-1.6%$1.76$1.23▼$12.23$18.51M-1.85165,549 shs41,344 shsXCURExicure$2.82+2.2%$3.40$2.62▼$9.75$17.98M3.5325,027 shs13,871 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMInMed Pharmaceuticals-1.31%-4.13%+143.16%+88.75%-45.49%KZIANovogen+0.70%+5.02%-18.44%+43.57%+118.63%TPSTTempest Therapeutics0.00%0.00%-34.54%-44.54%-85.70%XCURExicure-3.16%-10.39%-18.34%-30.39%-72.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMInMed Pharmaceuticals 1.00SellN/AN/AKZIANovogen 2.60Moderate Buy$23.7589.39% UpsideTPSTTempest Therapeutics 1.50ReduceN/AN/AXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest INM, KZIA, TPST, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026KZIANovogen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.005/28/2026XCURExicure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/21/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMInMed Pharmaceuticals$4.94M1.06N/AN/A$6.71 per share0.24KZIANovogen$42K493.54N/AN/A($5.34) per share-2.35TPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AXCURExicureN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMInMed Pharmaceuticals-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%N/AKZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/ATPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)XCURExicure-$4.95M-$1.55N/AN/AN/AN/A-179.41%-64.37%8/7/2026 (Estimated)Latest INM, KZIA, TPST, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026XCURExicure-$18.60-$0.29+$18.31-$0.29$1.64 millionN/A5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/6/2026Q3 2026INMInMed Pharmaceuticals-$94.4436-$0.69+$93.7536-$0.73$1.20 millionN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/A3/25/2026Q4 2025XCURExicure-$18.60-$0.46+$18.14-$0.46$1.64 millionN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINMInMed PharmaceuticalsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMInMed PharmaceuticalsN/A3.123.12KZIANovogenN/A2.87N/ATPSTTempest TherapeuticsN/A0.740.74XCURExicureN/A0.790.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMInMed Pharmaceuticals20.12%KZIANovogen30.89%TPSTTempest Therapeutics22.52%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipINMInMed Pharmaceuticals0.85%KZIANovogen1.00%TPSTTempest Therapeutics6.28%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMInMed Pharmaceuticals103.31 million3.29 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataTPSTTempest Therapeutics2014.81 million13.88 millionNo DataXCURExicure506.37 million3.01 millionNot OptionableINM, KZIA, TPST, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11 at 8:51 AM | finanznachrichten.deExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementJune 10 at 7:40 PM | markets.businessinsider.comExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 10 at 4:01 PM | globenewswire.comExicure Regains Nasdaq Compliance After Late Quarterly FilingJune 1, 2026 | tipranks.comExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QJune 1, 2026 | globenewswire.comExicure delays quarterly filing, trims quarterly lossMay 15, 2026 | tipranks.comExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comExicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem MeetingsJanuary 21, 2026 | quiverquant.comQExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsJanuary 21, 2026 | globenewswire.comSangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) StockDecember 11, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026MGM Buyout: The House Doesn't Always WinBy Jeffrey Neal Johnson | June 2, 2026The World Cup Is Coming—These 3 Stocks Could Cash InBy Chris Markoch | June 11, 2026INM, KZIA, TPST, and XCUR Company DescriptionsInMed Pharmaceuticals NASDAQ:INM$1.58 +0.07 (+4.64%) Closing price 04:00 PM EasternExtended Trading$1.56 -0.02 (-1.27%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Novogen NASDAQ:KZIA$12.54 +1.04 (+9.04%) Closing price 04:00 PM EasternExtended Trading$12.54 +0.01 (+0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Tempest Therapeutics NASDAQ:TPST$1.25 -0.02 (-1.57%) Closing price 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Exicure NASDAQ:XCUR$2.82 +0.06 (+2.17%) Closing price 03:59 PM EasternExtended Trading$3.00 +0.18 (+6.21%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
